Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Invasive infections caused by Candida krusei are a significant concern because this organism is intrinsically resistant to fluconazole. Voriconazole is more active than fluconazole against C. krusei in vitro. One mechanism of fluconazole resistance in C. krusei is diminished sensitivity of the target enzyme, cytochrome P450 sterol 14α-demethylase (CYP51), to inhibition by this drug. We investigated the interactions of fluconazole and voriconazole with the CYP51s of C. krusei (ckCYP51) and fluconazole-susceptible Candida albicans (caCYP51). We found that voriconazole was a more potent inhibitor of both ckCYP51 and caCYP51 in cell extracts than was fluconazole. Also, the ckCYP51 was less sensitive to inhibition by both drugs than was caCYP51. These results were confirmed by expressing the CYP51 genes from C. krusei and C. albicans in Saccharomyces cerevisiae and determining the susceptibility of the transformants to voriconazole and fluconazole. We constructed homology models of the CYP51s of C. albicans and C. krusei based on the crystal structure of CYP51 from Mycobacterium tuberculosis . These models predicted that voriconazole is a more potent inhibitor of both caCYP51 and ckCYP51 than is fluconazole, because the extra methyl group of voriconazole results in a stronger hydrophobic interaction with the aromatic amino acids in the substrate binding site and more extensive filling of this site. Although there are multiple differences in the predicted amino acid sequence of caCYP51 and ckCYP51, the models of the two enzymes were quite similar and the mechanism for the relative resistance of ckCYP51 to the azoles was not apparent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Mechanism of Fluconazole Resistance in Candida krusei
Orozco, A. S., Higginbotham, L. M., Hitchcock, C. A., Parkinson, T., Falconer, D., Ibrahim, A. S., Ghannoum, M. A., & Filler, S. G. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2645 · Cited by 218 · cited 7×
“albicans used in these experiments have similar amounts of CYP51 (17).”
BackgroundMethodResultInfluentialSelf-citationIdentification and expression of multidrug resistancerelated ABC transporter genes in Candida krusei
Katiyar, S. K., & Edlind, T. D. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.109.116 · Cited by 104
Talibi, D., & Raymond, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.1.231-240.1999 · Cited by 101
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
“krusei, is well known, and studies have demonstrated that the voriconazole activity against this species may be attributed to enhanced binding of this triazole to the target enzyme compared to that of fluconazole (15, 56, 58).”
ResultEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Metadata
- Authors
- Fukuoka, T., Johnston, D. A., Winslow, C. A., de Groot, M. J., Burt, C., Hitchcock, C. A., & Filler, S. G.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-04
- Volume
- 47
- Issue
- 4
- Pages
- 1213-1219
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2135021455
- Cited by
- 96
- References
- 4
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei. https://app.cochat.ai/papers/10.1128/aac.47.4.1213-1219.2003
- The paper
- Fukuoka, T., Johnston, D. A., Winslow, C. A., de Groot, M. J., Burt, C., Hitchcock, C. A., & Filler, S. G. (2003). Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.47.4.1213-1219.2003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.